Print（PDF/132KB） Jan. 31, 2025 Finances

Notice Concerning Finance Income

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; Securities Code: 4506, Prime Market of TSE) announced today that it recorded finance income for third quarter of the fiscal year ending March 31, 2025 (from April 1, 2024 to December 31, 2024) as follows.

1.Details of Finance Income

The Company recorded a foreign exchange gain of 14,975 million yen under finance income for the nine months ended December 31, 2024 due to recent fluctuations in foreign exchange rates. This was mainly due to the valuation of foreign currency-denominated liabilities held by its overseas subsidiaries.

In addition, foreign exchange gain of 36,454 million yen was recorded in the three months ended December 31, 2024, because financial costs (foreign exchange loss) of 21,479 million yen was recorded in the six months ended September 30, 2024.

2.Future Outlook

Regarding the impact of the above finance income on the results of the Company operations, please refer to the “Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2025 [IFRS]” announced today.